Anti-CS3 IgG Avidity Indices from a Pediatric ETEC Vaccine Trial in Zambia

Avidity index data for anti-CS3 and anti-LTB IgG antibodies from a clinical trial of the ETVAX® vaccine in Zambian children. The dataset includes measurements from 60 children aged 6–23 months taken at baseline and after multiple vaccine doses. It was created by Cynthia Mubanga and last updated in May 2026.

Use Cases

• Analyzing the relationship between antibody avidity and titre-defined naïve status based on the receiver operating characteristic (ROC) analysis results.
• Comparing vaccine-induced changes in antibody avidity over time based on measurements taken at baseline, day 22, and day 97.
• Investigating functional naivety in endemic populations based on the classification of children with detectable titres but low avidity.
• Assessing inter-individual variability in antibody quality based on the avidity index results reported for CS3 and LTB.

Strengths

• Includes data from 60 pediatric participants, providing a cohort for analysis.
• Contains longitudinal measurements taken at three time points (baseline, day 22, day 97).
• Reports specific statistical results, such as mean CS3 IgG avidity decreasing from 0.7 to 0.6 (p < 0.001).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 15.2 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Plasma samples from a clinical trial were analyzed by limiting antigen dilution ELISA to calculate avidity indices.

Time Range

Measurements taken from baseline to day 97 post-vaccination.

Freshness

Last updated 2026-05-15 17:25:36; freshness should be verified.

Geography

Data collected from Zambian children.